Literature DB >> 16964590

Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.

Thomas Decaens1, Françoise Roudot-Thoraval, Solange Hadni-Bresson, Carole Meyer, Jean Gugenheim, Francois Durand, Pierre-Henri Bernard, Olivier Boillot, Laurent Sulpice, Yvon Calmus, Jean Hardwigsen, Christian Ducerf, Georges-Philippe Pageaux, Sebastien Dharancy, Olivier Chazouilleres, Daniel Cherqui, Christophe Duvoux.   

Abstract

Orthotopic liver transplantation (OLT) indication for hepatocellular carcinoma (HCC) is currently based on the Milan criteria. The University of California, San Francisco (UCSF) recently proposed an expansion of the selection criteria according to tumors characteristics on the explanted liver. This study: 1) assessed the validity of these criteria in an independent large series and 2) tested for the usefulness of these criteria when applied to pre-OLT tumor evaluation. Between 1985 and 1998, 479 patients were listed for liver transplantation (LT) for HCC and 467 were transplanted. According to pre-OLT (imaging at date of listing) or post-OLT (explanted liver) tumor characteristics, patients were retrospectively classified according to both the Milan and UCSF criteria. The 5-yr survival statistics were assessed by the Kaplan-Meier method and compared by the log-rank test. Pre-OLT UCSF criteria were analyzed according to an intention-to-treat principle. Based on the pre-OLT evaluation, 279 patients were Milan+, 44 patients were UCSF+ but Milan- (subgroup of patients that might benefit from the expansion), and 145 patients were UCSF- and Milan-. With a short median waiting time of 4 months, 5-yr survival was 60.1 +/- 3.0%, 45.6 +/- 7.8%, and 34.7 +/- 4.0%, respectively (P < 0.001). The 5-yr survival was arithmetically lower in UCSF+ Milan- patients compared to Milan+ but this difference was not significant (P = 0.10). Based on pathological features of the explanted liver, 5-yr survival was 70.4 +/- 3.4%, 63.6 +/- 7.8%, and 34.1 +/- 3.1%, in Milan+ patients (n = 184), UCSF+ Milan- patients (n = 39), and UCSF- Milan- patients (n = 238), respectively (P < 0.001). However, the 5-yr survival did not differ between Milan+ and UCSF+ Milan- patients (P = 0.33). In conclusion, these results show that when applied to pre-OLT evaluation, the UCSF criteria are associated with a 5-yr survival below 50%. Their applicability is therefore limited, despite similar survival rates compared to the Milan criteria, when the explanted liver is taken into account.

Entities:  

Mesh:

Year:  2006        PMID: 16964590     DOI: 10.1002/lt.20884

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  36 in total

1.  Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma.

Authors:  Tarkan Unek; Sedat Karademir; Naciye Cigdem Arslan; Tufan Egeli; Gulsen Atasoy; Ozgul Sagol; Funda Obuz; Mesut Akarsu; Ibrahim Astarcioglu
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

Review 2.  Surgical management of hepatocellular carcinoma.

Authors:  Tony Cy Pang; Vincent Wt Lam
Journal:  World J Hepatol       Date:  2015-02-27

3.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

4.  Twenty years of Milan criteria: the wicked flee though no one pursues.

Authors:  Giovanni Battista Levi Sandri; Francesco Guerra; Quirino Lai
Journal:  Hepatobiliary Surg Nutr       Date:  2016-08       Impact factor: 7.293

5.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

6.  Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.

Authors:  Francis Y Yao; Neil Mehta; Jennifer Flemming; Jennifer Dodge; Bilal Hameed; Oren Fix; Ryutaro Hirose; Nicholas Fidelman; Robert K Kerlan; John P Roberts
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

Review 7.  Recent advances in the surgical treatment of hepatocellular carcinoma.

Authors:  Zenichi Morise; Norihiko Kawabe; Hirokazu Tomishige; Hidetoshi Nagata; Jin Kawase; Satoshi Arakawa; Rie Yoshida; Masashi Isetani
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

8.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

9.  Liver Transplantation for HCC: A Review.

Authors:  Rahul Kakodkar; A S Soin
Journal:  Indian J Surg       Date:  2011-12-27       Impact factor: 0.656

Review 10.  Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage.

Authors:  Adam Bartlett; Nigel Heaton
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.